ArticleScientific reports2024

Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.

Li Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.